Repairing the Patient Journey: How Pharma Can Fix the Obvious – and Not So Obvious – Breaking Points of Nonadherence

When nearly half of all treatment failures stem from nonadherence, the stakes for patients, and for pharma, could not be higher.

One of the most persistent barriers in healthcare, leading to preventable hospitalizations, lost lives and billions in avoidable costs each year, is patient nonadherence. The reasons are complex, ranging from access and affordability challenges to low health literacy and rising distrust in pharma, but the impact is universal: patients don’t achieve the outcomes they deserve.

From predictive analytics and telehealth to omnichannel engagement and generative AI, new solutions are redefining how to build trust, improve access and support patients across every stage of the treatment journey. The article demonstrates how EVERSANA’s innovative commercialization models is transforming the affordability, access and adherence landscape.

By blending high-tech platforms with high-touch patient services, EVERSANA delivers a model that simplifies affordability, accelerates time to therapy and empowers patients to stay on treatment. For manufacturers, this represents a blueprint for achieving both improved outcomes and stronger brand value in today’s evolving healthcare landscape.

How can manufacturers transform adherence into sustained outcomes?

• Improve transparency with real-time benefits verification

• Expand access through telehealth and predictive analytics

• Build trust with patient-first services and education

• Enhance engagement via omnichannel and AI-driven support

• Empower patients with personalized affordability and adherence tools

Ready to address adherence challenges head-on? Read the full article to uncover actionable strategies and insights that put patients at the center and deliver measurable results for manufacturers.